Industry Insights

1. It’s Time To Rethink Shoe-Horning Cell And Gene Therapies Into A Pharma Business 7/6/2020

   Companies have more options to incorporate cell and gene therapies (CGT) into their operations.

2. Early Data Demonstrate Strengths of Gene Therapy Approaches for Sanfilippo Syndrome 7/6/2020

   Initial safety and efficacy data from two clinical trials evaluating gene therapies for Sanfilippo syndrome were presented at the ASGCT 23rd Annual Meeting.

3. Top 5 Mistakes To Avoid When Measuring Overall Equipment Effectiveness 6/22/2020

   Despite its (apparently) trivial formulation, overall equipment effectiveness (OEE) is one of the most misleading key performance indicators ever used in the manufacturing world. This article examines five common mistakes you'll want to avoid when dealing with OEE.

4. 4 Preparatory Moves For A Post-COVID World 6/19/2020

   While we don’t know how different the post-COVID world will be, we do know that pharma and medtech leaders are looking ahead and planning to work differently.

5. Successful Treatment Options For Rare Diseases Demand Innovative, Compliant Patient Services Programs 6/15/2020

   While this is an exciting time for potential patients and the industry, without carefully plotted paths to access, the patients who need these novel therapies may encounter many roadblocks, and manufacturers may be putting their innovation at risk.

6. Developing Cell Therapy Packaging And Labeling Is A Time Critical Activity 6/10/2020

   Supply chain and regulatory personnel familiar with drug product packaging have likely experienced the scramble of getting packaging layouts and text into regulatory filings, getting quality agreements with packaging and transport service providers in place, and completing packaging qualification protocols at the last minute.

7. Advances In Manufacturing Key To Making Cell And Gene Therapies Accessible 6/9/2020

   For innovative and novel therapies to become accessible to the patients who desperately need them, they must successfully move through all phases of clinical trial and ultimately, prove to be commercially viable. The challenges in the development and manufacturing of cell and gene therapies are not insignificant, however.

8. Dendritic Cells For Cancer Treatment: Future Therapeutic Avenues 6/3/2020

   Dendritic Cell-based therapies have emerged as an exciting avenue of cell-based therapy due to their unique function as Antigen Presenting Cells (APCs) and subsequent ability to activate T cells with antitumorigenic effect.

9. From Hope To Reality: The Potential Of Hematopoietic Stem Cell Gene Therapy In Rare Diseases And Beyond 6/2/2020

   HSC gene therapy specifically holds great promise against otherwise intractable diseases, due to its advantages of potential durability and ability for gene-modified HSCs to differentiate into multiple new cell types and migrate and deliver genes into multiple different organ systems and tissues.

10. Future Workforce Talent In Philadelphia’s CGT Sector 5/29/2020

    Listen in as Sarah Steltz, executive director, University City District’s West Philadelphia Skills Initiative, speaks specifically to the future job opportunities in Philadelphia’s cell and gene sector that go well beyond scientists, researchers, and Ph.D.’s.